146results about How to "Reduce hemolysis" patented technology

A cannulation system for cardiac support uses an inner cannula disposed within an outer cannula. The outer cannula includes a fluid inlet for placement within the right atrium of a heart. The inner cannula includes a fluid inlet extending through the fluid inlet of the outer cannula and the atrial septum for placement within at least one of the left atrium and left ventricle of the heart. The cannulation system also employs a pumping assembly coupled to the inner and outer cannulas to withdraw blood from the right atrium for delivery to the pulmonary artery to provide right heart support, or to withdraw blood from at least one of the left atrium and left ventricle for delivery into the aorta to provide left heart support, or both.

Embodiments of the present invention relate generally to certain types of reciprocating positive-displacement pumps (which may be referred to hereinafter as “pods,”“pump pods,” or “pod pumps”) used to pump fluids, such as a biological fluid (e.g., blood or peritoneal fluid), a therapeutic fluid (e.g., a medication solution), or a surfactant fluid. The pumps may be configured specifically to impart low shear forces and low turbulence on the fluid as the fluid is pumped from an inlet to an outlet. Such pumps may be particularly useful in pumping fluids that may be damaged by such shear forces (e.g., blood, and particularly heated blood, which is prone to hemolysis) or turbulence (e.g., surfactants or other fluids that may foam or otherwise be damaged or become unstable in the presence of turbulence).

A rotary blood pump is provided which includes a pump housing and a rotor mounted for rotation with the housing. The rotor has an impeller. A rotor motor is provided including a plurality of permanent magnets carried by the impeller. A first motor stator is positioned on one side of the impeller and a second motor stator is positioned on an opposite side of the impeller. The motor stators each include a plurality of electrically conductive coils and pole pieces located within the housing. A plurality of wedge-shaped hydrodynamic thrust bearings are located outside of the axis of the rotor. During rotation of the impeller, the hydrodynamic bearings are separated from the housing by a fluid film and are not in direct mechanical contact with the housing.

A sulfoalkyl ether-alkyl ether cyclodextrin (SAE-AE-CD) derivative is provided. The SAE-AE-CD possesses advantages over known SAE-CD and AE-CD derivatives as well as over the parent cyclodextrin by being more water soluble and less membrane disturbing. The SAE-AE-CD includes at least one sulfoalkyl ether group and at least one alkyl ether group even though the degree of substitution for the functional groups can be different. The SAE functional group can be present in molar excess over the AE functional group and vice versa. The total degree of substitution of the cyclodextrin, with respect to both functional groups, can be varied such that a minority or a majority of the hydroxyl moieties of the CD are derivatized. The SAE-AE-CD derivative can be used to solubilize compounds with insufficient water solubility. In some cases, they also stabilize compounds in solution against degradation or to solubilize degradation products formed during degradation. In addition, SAE-AE-CD can also be used for other purposes such as osmotic agents, agents used to mask the taste of problematic drugs. Surprisingly, while AE-CDs are known to be toxic by being membrane disturbing, SAE-AE-CDs are less membrane disturbing and therefore have greater safety.

A sulfoalkyl ether-alkyl ether cyclodextrin (SAE-AE-CD) derivative is provided. The SAE-AE-CD possesses advantages over known SAE-CD and AE-CD derivatives as well as over the parent cyclodextrin by being more water soluble and less membrane disturbing. The SAE-AE-CD includes at least one sulfoalkyl ether group and at least one alkyl ether group even though the degree of substitution for the functional groups can be different. The SAE functional group can be present in molar excess over the AE functional group and vice versa. The total degree of substitution of the cyclodextrin, with respect to both functional groups, can be varied such that a minority or a majority of the hydroxyl moieties of the CD are derivatized. The SAE-AE-CD derivative can be used to solubilize compounds with insufficient water solubility. In some cases, they also stabilize compounds in solution against degradation or to solubilize degradation products formed during degradation. In addition, SAE-AE-CD can also be used for other purposes such as osmotic agents, agents used to mask the taste of problematic drugs. Surprisingly, while AE-CDs are known to be toxic by being membrane disturbing, SAE-AE-CDs are less membrane disturbing and therefore have greater safety.

A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents. The red blood cell storage composition preferably includes reagents selected from: modifiers of glycolytic / metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger molecules, and combinations thereof.

An apparatus and methods for enhanced plasmapheresis comprising a filter membrane under an orbital motion or movement that has optimal local shear forces and maximum plasma flow output. The methods for biological separation and therapies comprise platelet collection, viral particle removal, cell washing and processing for stem cell selection, bone marrow purging, red blood cell collection, auto-transfusion, auto-immune disease treatment, selective macro-molecule removal, toxin removal, LDL removal, extracorporeal plasma delipidation, and the like.

There is provided a non-contact, passively suspended blood pump that includes (a) a housing; (b) a pump rotor within the housing, wherein the pump rotor has a first end and a second end, and an axis of rotation; (c) a first axial thrust bearing across a first axial gap, between the first end and the housing, that axially suspends the first end; (d) a second axial thrust bearing across a second axial gap, between the second end and the housing, that axially suspends the second end; (e) a first radial hydrodynamic bearing that radially suspends the first end; and (f) a second radial hydrodynamic bearing that radially suspends the second end. Determining pump differential pressure by monitoring rotor axial position allows automatic physiologic control.

A cannulation system for cardiac support uses an inner cannula disposed within an outer cannula. The outer cannula includes a fluid inlet for placement within the right atrium of a heart. The inner cannula includes a fluid inlet extending through the fluid inlet of the outer cannula and the atrial septum for placement within at least one of the left atrium and left ventricle of the heart. The cannulation system also employs a pumping assembly coupled to the inner and outer cannulas to withdraw blood from the right atrium for delivery to the pulmonary artery to provide right heart support, or to withdraw blood from at least one of the left atrium and left ventricle for delivery into the aorta to provide left heart support, or both.

The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal body fluid system.

The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal blood system.

The invention relates to an embedded micro streamline axial flow blood pump, which can be used for assisting blood circulation of failed heart. The blood pump comprises a pump body arranged in a sleeve body and a driving device arranged outside the pump body, wherein the pump body comprises the sleeve body, a front guide vane, a rotor and a back guide vane; the hubs of the front guide vane, a rotor and the back guide vane are designed integrally in an integral streamline form; and the front half part of the rotor is provided with an inductive blade. The blood pump can reduce the on-way pressure loss of the blood in the flow channel of the blood pump, improve efficiency and reduce hemolysis; and can promote the circumferential speed of the blood after entering into a rotor area due to the inductive blade arranged on the front half part of the rotor, and avoids the occurrence of vacuole phenomenon.

Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders.

Pharmaceutical compositions for intravenous administration comprising the compound of Formula Ior pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and / or emesis with the pharmaceutical compositions are also described herein.

An implantable cardiovascular blood pump system is provided, suitable for use as a left ventricular assist device (LVAD) system, having an implantable cardiovascular pump, an extracorporeal battery and a controller coupled to the implantable pump, and a programmer selectively periodically coupled to the controller to configure and adjust operating parameters of the implantable cardiovascular pump. The implantable cardiovascular blood pump includes a coaxial inflow cannula and outflow cannula in fluid communication with one another and with a pumping mechanism. The pumping mechanism may be a vibrating membrane pump which may include a flexible membrane coupled to an electromagnetic actuator assembly that causes wavelike undulations to propagate along the flexible membrane to propel blood through the implantable cardiovascular pump. The implantable cardiovascular pump may be programmed to operate at frequencies and duty cycles that mimic physiologic flow rates and pulsatility while avoiding thrombus formation, hemolysis and / or platelet activation.

The invention relates to a series of polyethylene glycol modified cationic antibacterial peptide with different molecular weight. The modified antibacterial peptide is self-assembled into a nanometer micelle in an aqueous medium. The formation of the micelle can play a role in protecting the antibacterial peptide and weakening the degradation effect of protease on the antibacterial peptide, and simultaneously improves the stability and antibacterial activity of polypeptide in serum. In addition, the modification of polyethylene glycol obviously reduces the hemolytic toxic side effects of the antibacterial peptide.

The invention provides a preparation method and activity detection for antibacterial peptides. In the preparation method, series of antibacterial peptides which contain a few amino acid residues are prepared by using a helical wheel model of a protein; and antibacterial activity, hemolytic activity, cytotoxicity and the like of the series of the antibacterial peptides are detected. The four obtained antibacterial peptides have obvious bacteriostatic activity; and the two antibacterial peptides which contain a plurality of valines have no hemolytic activity and less cytotoxicity, wherein in particular the antibacterial peptides which contain three glycines, five arginines and eight valines have the greatest potential. The preparation method and the activity detection have important theoretical and practical significance for further explaining the action mechanism of the antibacterial peptides, designing the antibacterial peptides reasonably and the like.

The invention relates to an embeddable two-stage axial flow blood pump rotor structure. The embeddable two-stage axial flow blood pump rotor structure comprises a rotor head part, a rotor tail part and an impeller part, wherein the impeller part which adopts a two-stage structure design comprises a front-stage impeller and a back-stage impeller; the front-stage impeller (2) in a spiral structure has three blades; the back-stage impeller (3) is in a traditional axial flow structure; an axial distance is arranged between the front-stage impeller and the back-stage impeller; the surface curve equation of the heat part of the rotor is as follows: Formula, wherein the x is an axial distance of a hub; the y is a radial distance of the hub; and the original point is an intersection point of the surface curve of the head part of the rotor and the axial line of the hub. The embeddable two-stage axial flow blood pump rotor structure can enable the blood pump rotor to satisfy with a lift requirement at a relatively low rotating speed under the precondition that the axial size is as small as possible, thereby decreasing formation of hemolysis and reducing power consumption efficiently, and can reduce irregular flow resulted from the more complex blood pump rotor structure as the transition between the front and back impellers is corrected.

Pharmaceutical compositions for intravenous administration comprising the compound of Formula Ior pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and / or emesis with the pharmaceutical compositions are also described herein.

The devices of the present disclosure are rheolytic thrombectomy catheters with a self-inflating distal balloon. A self-inflating balloon is located distal to an inflow gap or orifice and distal to a fluid jet emanator, which self-inflating balloon is inflated and expanded by the utilization of internal operating forces consisting of forwardly directed high velocity fluid jet streams and / or entrained thrombus particulate therein. The self-inflating balloon, when inflated, impinges on the wall of the blood vessel to isolate sections of the blood vessel distal and proximal to the inflated balloon in order to prevent flow of thrombus particulate, fluids and the like distal to the self-inflating balloon and to provide a stagnant nonflow region proximal to the self-inflating balloon. The devices of the present disclosure also provide for a uniform spacing of the catheter tube with respect to the thrombus and / or wall of the blood vessel.

The devices of the present disclosure are rheolytic thrombectomy catheters with a self-inflating distal balloon. A self-inflating balloon is located distal to an inflow gap or orifice and distal to a fluid jet emanator, which self-inflating balloon is inflated and expanded by the utilization of internal operating forces consisting of forwardly directed high velocity fluid jet streams and / or entrained thrombus particulate therein. The self-inflating balloon, when inflated, impinges on the wall of the blood vessel to isolate sections of the blood vessel distal and proximal to the inflated balloon in order to prevent flow of thrombus particulate, fluids and the like distal to the self-inflating balloon and to provide a stagnant nonflow region proximal to the self-inflating balloon. The devices of the present disclosure also provide for a uniform spacing of the catheter tube with respect to the thrombus and / or wall of the blood vessel.

The invention belongs to the field of biomedical engineering and particularly relates to an intrusive assisted circulation device used in the department of cardiac surgery. The device is characterized in that a magnetic drive mode is adopted for power transmission. The device is divided into two parts, namely an invitro driving device and an auxiliary device capable of being implanting into a human body through percutaneous coronary intervention, wherein an invitro driving device main body is a rotating magnetic field generation device capable of generating a rotating magnetic field which is strong enough; the auxiliary device implanted into the human body is internally provided with a minitype axial flow pump; a high-energy magnet is embedded in an impeller of the minitype axial flow pump, and is driven to rotate by the rotating magnetic field so as to push blood to flow; and the pump is implanted into the part, crossing over an aortic valve or pulmonic valve, of a heart, so as to play a role in assisting the heart to pump blood, thus effectively relieving the cardiac muscle load and assisting heart recovery.

The invention discloses a half-blade-rotor-type axial flow blood pump which comprises an inner barrel, a front guide, a rotor and a rear guide. The front guide has three straight blades, the rotor has two rotating blades, the two rotating blades of half-blade structures are distributed on a front half of a hub of the rotor only, and blade tip clearance length of the rotor is reduced by a half; the rear guide has three big rotating blades and three small rotating blades, the big rotating blades and the small rotating blades are distributed at intervals, each big rotating blade is provided with a suspension arm with one-half length, each suspension arm extends into a rotor area to form a suspension arm blade structure, and a runner portion on the outer surface of the rotor is made by smooth date-pit-shaped cubic spline curves. The half-blade-rotor-type axial flow blood pump has the advantages that a whole runner formed by the front guide, the rotor and the rear guide is designed to be of a date-pit-shaped structure, and the smooth cubic spline curves are adopted, so that pressure rise of the blood pump is increased, flow field distribution in the pump is improved, area of a rotating-stilling interface is reduced, and risk of thrombosis at a bearing is lowered.

The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal body fluid system.

A docetaxel inclusion complex having improved water-solubility (up to 15 mg / ml) and stability (stability constant Ka=2056M−1-13051M−1), comprises docetaxel and hydroxypropyl-beta-cyclodextrin and / or sulfobutyl-beta-cyclodextrin in a ratio of 1:10-150. The method includes steps as follows: docetaxel dissolved in ethanol is added into water solution of cyclodextrin via stirring, until docetaxel is completely dissolved; said solution is filtered in 0.2-04 μm microporous membrane then ethanol is removed through reduced pressure to obtain the inclusion complex in a liquid form; or ethanol, followed by water is removed through reduced pressure, then dried to obtain the inclusion complex in a solid form.

The invention relates to an apparatus system and methods for treatment of virus-infected or pathogen-loaded human blood components separated from normal components comprising a separation apparatus and treatment apparatus system that inactivate pathogens in an extracorporeal body fluid system.

The invention discloses a low-blood-loss micro axial-flow type artificial heart which comprises a vane wheel, a motor rotor, and a motor stator, wherein the vane wheel is arranged inside the motor rotor in an interference fit and coaxial mode, the vane wheel is placed between an entry guide vane and an exit guide vane, two flow-guiding cones with large ends of 3mm are respectively arranged on an inlet end of the entry guide vane and an outlet end of the exit guide vane, the conical degree of the flow-guide cone is 90 degrees, and the two flow-guiding cones are in symmetrical arrangement. The helical angle of each flow-guiding vane on the entry guide vane gradually reduces from 90 degrees to 30 degrees along the axial direction from the inlet end to the outlet end, and the helical angle of each flow-guiding vane on the exit guide vane 3 gradually increases from 30 degrees to 90 degrees along the axial direction from the inlet end to the outlet end. The vanes on the vane wheel and all the flow-guiding vanes are in the shape of a logarithm helical line. Shaftless drive of the vane wheel reduces thrombus risk, and the micro structure improves the ability to implant. The low-blood-loss micro axial-flow type artificial heart has the advantages of being low in hemolysis, strong in implanting ability, simple in structure, high in reliability and the like.

The invention relates to a red cell storage solution and a preparation method thereof. The storage solution comprises a buffering system, a nutritional system, an osmotic pressure system and an anticorrosion system, wherein the anticorrosion system comprises the following components according to mass concentration: 0.2-1g / L of chloramphenicol, 0.1-0.6g / L of neomycin sulfate, and 0.1-0.5g / L of gentamicin. Through mutual concurrent effects of the buffering system, the nutritional system, the anticorrosion system and the osmotic pressure system of the red cell storage solution provided by the invention, long storage cycle of the red cell storage solution is ensured, at the end of the sixth month of the storage, that red cell suspension free hemoglobin concentration still conforms to national standard is detected, and the hemolysis ratio at the end of the storage is smaller than 0.8 percent of the total of red cells; the red cell storage solution provided by the invention can ensure relatively strong antigenic activity and stability of the red cells.